Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.
Back
Bridging the Gaps in Prostate Cancer
The areas of expert consensus identified during the meeting will be disseminated through peer-reviewed manuscripts to provide guidance to practicing clinicians, particularly community oncologists.
Bridging the Gaps in Prostate Cancer
Episodes
All
All
Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.
Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.
Dr Shore discusses advances that have been achieved with AR-directed agents in prostate cancer and considerations for the optimal use of these agents.
Evan Y. Yu, MD, discusses the potential utility of AR degradation, mutation inhibition, and suppression for patients with metastatic prostate cancer.
Neal Shore, MD, FACS, discusses gaps in prostate cancer management and future research directions that may optimize care for high-risk localized disease.
Benjamin L. Maughan, MD, PharmD, discusses the need for improved update of treatment intensification in metastatic hormone-sensitive prostate cancer.
Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
3
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
4
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
5